






 Cite this: *RSC Adv.*, 2022, 12, 6292

Antiurease screening of alkyl chain-linked thiourea derivatives: *in vitro* biological activities, molecular docking, and dynamic simulations studies†

 Sana Yaqoob,^a Abdul Hameed,^b  *^{ab} Mahmood Ahmed,^c  *^c Muhammad Imran,^d  ^d Muhammad Abdul Qadir,^e Mahwish Ramzan,^f Numan Yousaf,^f Jamshed Iqbal^g and Muhammad Muddassar  *^f

Urease has become an important therapeutic target because it stimulates the pathogenesis of many human health conditions, such as pyelonephritis, the development of urolithiasis, hepatic encephalopathy, peptic ulcers, gastritis and gastric cancer. A series of alkyl chain-linked thiourea derivatives were synthesized to screen for urease inhibition activity. Structure elucidation of these compounds was done by spectral studies, such as IR, ¹H NMR and ¹³C NMR, and MS analysis. *In vitro* urease enzyme inhibition assay revealed that compound **3c** was the most potent thiourea derivative among the series with IC₅₀ values of 10.65 ± 0.45 μM, while compound **3g** also exhibited good activity with an IC₅₀ value of 15.19 ± 0.58 μM compared to standard thiourea with an IC₅₀ value of 15.51 ± 0.11 μM. The other compounds in the series possessed moderate to weak urease inhibition activity with IC₅₀ values ranging from 20.16 ± 0.48 to 60.11 ± 0.78 μM. The most potent compounds **3c** and **3g** were docked to jack bean urease (PDB ID: 4H9M) to evaluate their binding affinities and to find the plausible binding poses. The docked complexes were refined through 100 ns-long MD simulations. The simulation results revealed that the average RMSD of **3c** was less than that of the **3g** compound. Furthermore, the radius of gyration plots for both complexes showed that **3c** and **3g** docking predicted binding modes did not induce any conformational change in the urease structure.

Received 28th November 2021

Accepted 8th February 2022

DOI: 10.1039/d1ra08694d

rsc.li/rsc-advances

1. Introduction

Urease (E.C.3.5.1.5) is a metal containing enzyme that is similar to amidohydrolases and is common in nature, being present in diverse varieties of microbes, animals, and plants, and it cleaves urea into carbon dioxide and ammonia.^{1,2} Urease provides an aid for the survival of *Helicobacter pylori* (*H. pylori*) in the stomach at low pH, which can stimulate the pathogenesis of many human health conditions, such as pyelonephritis, the development of

urolithiasis, hepatic encephalopathy, peptic ulcer, gastritis and gastric cancer.^{3–5} Rapid diagnostic testing of urease is a precursor to diagnose *H. pylori* in the stomach because it depends on urease activity for its sustainability in the stomach at low pH.^{6,7} Urease from plants and bacteria have a common ancestral gene due to which they have no difference in sequence and have the same active sites, so jack bean urease was used here as a prototype for its study and characterization.^{8,9} Urease from jack beans has one catalytic subunit and two structural subunits, so it exists in trimeric form and the active site contains 840 amino acids and Ni²⁺ is present in the active site for its catalytic mechanism.¹⁰ Homohexameric molecules comprising six α subunits are present in urease from jack beans, whereas urease from bacteria comprises three different subunits, namely α, β, and γ, and despite the structural dissimilarity, the active site is always located on α subunits consisting of a binuclear nickel center.^{11,12}

Due to the association of urease with different bacterial infections, various types of urease inhibitors have been synthesized, such as Schiff bases-sulfonamides, phosphate derivatives, thiourea derivatives, hydroxamic acid, chelators of nickel atoms at the active site, thiolate compounds, analogs of barbituric acid (thiobarbiturates, barbiturates), and thiosemicarbazones.^{13–16} The structures of some good urease inhibitors previously reported are presented in Fig. 1. Thiourea has shown diverse pharmacological

^aH. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. E-mail: abdul_hameed8@hotmail.com

^bDepartment of Chemistry, University of Sahiwal, Sahiwal, Pakistan

^cDepartment of Chemistry, Division of Science and Technology, University of Education, College Road, Lahore, Pakistan. E-mail: mahmoodresearchscholar@gmail.com

^dKAM-School of Life Sciences, FC College (A Chartered University), Lahore, Pakistan

^eSchool of Chemistry, University of the Punjab, Lahore, Pakistan

^fDepartment of Biosciences, COMSATS University Islamabad, Park Road, Islamabad, Pakistan. E-mail: mmuddassar@comsats.edu.pk

^gCenter for Advanced Drug Research, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra08694d






Fig. 1 Previously identified scaffolds (a–c)^{14,18,19} and the structural framework (d) of target study as urease inhibitor.

applications to serve as antioxidant, anti-inflammatory, antibacterial, antihypertensive, and anticancer agents.¹⁷ Keeping in view the importance of urea and the thiourea moiety, we synthesized a thiourea moiety, sandwiched between a short lipophilic chain and phenyl residue-based molecules to screen them as urease inhibitors to find leads as potential drug candidates. Moreover, the close resemblance of thiourea moiety-based molecules with the reference thiourea would be an additional benefit in finding a new urease inhibitor. Enzyme kinetics, molecular docking, and molecular dynamic (MD) simulation studies were also carried out, respectively, to get an insight into the inhibition mechanism and binding conformation of competitive inhibitors in the jack bean urease enzyme.

2. Experimental

All the reagents and solvents for the different reactions and purification were purchased from commercial suppliers (Falcon Scientific, Lahore, Hajvery Chemicals, Karachi and Central Scientific Store, Lahore, India) and were of analytical grade and used without further purification. High-purity water was prepared in our laboratory using the Milli-Q® water system, UK. The progress of the reactions was observed by thin layer chromatography (TLC), where, after spotting the pre-coated silica plates (Merck, Germany), the spots were visualized under ultraviolet (UV) light; while the Stuart® apparatus (Cole-Parmer, UK) was used to determine the melting points (mp) of all the products. IR (range, 4000–500 cm⁻¹), ¹H-NMR (300–500 MHz), and ¹³C-NMR (125 MHz) spectra were recorded by an FTIR spectrophotometer and NMR spectrometer, respectively, from Bruker Technologies (USA) to elucidate the structures of the newly synthesized compounds, while the *m/z* ratio was determined by mass spectrometry (Finnigan MAT-321A, Germany). Chemical shifts (δ , in ppm) and the coupling constant (*J*, in Hz) were reported using DMSO-*d*₆ as the solvent, whereas SiMe₄ was used as the internal standard.

2.1. General procedure for the synthesis of the thiourea-based molecules

Lauroyl chloride/caproyl chloride (5.0 mmol, 700 μ L) were taken in an oven-dried round-bottom flask (25 mL), and then

potassium thiocyanate solution (7.5 mmol, 729 mg in acetone) was added dropwise while stirring, and then the reaction mixture was refluxed at 50–60 °C for 1 h. The reaction mixture was placed at room temperature until it cooled down, and then substituted aniline (5.0 mmol, 840 mg in acetone) was added, and the mixture was refluxed again at 50–60 °C until the completion of the reaction, with the progress of the reactions observed by TLC (*n*-hexane, ethyl acetate as the solvent). Here, after spotting the pre-coated silica plates, the spots were visualized under ultraviolet (UV) light. After the completion of the reaction, the reaction mixture was ice cooled, and precipitates were formed, which were filtered and re-crystallized by employing absolute ethanol.

2.1.1. *N*-((4'-Methoxy-2'-nitrophenyl) carbamothioyl) dodecanamide (3a).
2.1.2. *N*-((4'-(Trifluoromethyl) phenyl) carbamothioyl) dodecanamide (3b). White crystals, yield 66%, mp 82–84 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3447 (–NH), 3321, 2920, 2852, 1673 (C=O), 1614, 1535, 1326, 1165, 1068, 840, 720. EI-MS *m/z* (%), 402.1 (36.4), 219 (12.5), 198.1 (7.8), 184.1 (6.8); ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.69 (1H, s, NH), 11.54 (1H, s, NH), 7.91 (2H, d, *J*_{3',2'/5',6'} = 8.4 Hz, H-3', H-5'), 7.76 (2H, d, *J*_{2',3'/6',5'} = 8.7 Hz, H-2', H-6'), 2.45 (*obscured by DMSO signal*, H-2), 1.57 (2H, app q, *J*₃ = 6.9 Hz, H-3), 1.23 (8H, m), 0.86 (3H, t, *J*₁₂ = 6 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 179.07 (C=S), 175.56 (C=O), 141.5 (Ar-C), 134.8 (Ar-C), 125.74 (Ar-CH \times 2), 125.69 (Ar-CH \times 2), 124.4 (CF₃), 35.72 (CH₂), 31.2 (CH₂), 28.9 (CH₂ \times 2), 28.7 (CH₂), 28.6 (CH₂ \times 2), 28.4 (CH₂), 24.2 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (*M*⁺ – 1): calculated for C₂₀H₂₉O₁N₂F₃S₁ (*M*): *m/z* 402.1953 found 402.1953.

2.1.3. *N*-((2'-Bromophenyl) carbamothioyl) octanamide (3c). Light brown color, yield 69%, mp 87–89 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3192 (–NH), 3029, 2921, 2854, 1701 (C=O), 1547, 1466, 1443, 1170, 1072, 906, 748, 611, 536. FAB (+ve) 357.1 (*M* + 1) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.41 (1H, s, NH), 11.58 (1H, s, NH), 7.88 (1H, app dd, *J*_{3',4'} = 8.0 Hz, *J*_{3',5'} = 1.2 Hz, H-3'), 7.71 (1H, app dd, *J*_{6',5'} = 8.0 Hz, *J*_{6',4'} = 1.2 Hz, H-6'), 7.43 (1H, td, *J*_{5',(6',4')} = 8.0 Hz, *J*_{5',3'} = 1.2 Hz, H-5'), 7.24 (1H, td, *J*_{4',(5',3')} = 8.0 Hz, *J*_{4',6'} = 1.2 Hz, H-4'), 2.49 (*obscured by DMSO signal*, H-2), 1.57 (2H, q, *J*₃ = 12.0 Hz, H-3), 1.26 (8H, m), 0.87 (3H, t, *J*₈ = 6.0 Hz, H-8); ¹³C-NMR (100 MHz, DMSO-*d*₆): δ_{C} 180.0 (C=S), 175.6 (C=O), 136.6 (Ar-C), 132.6 (Ar-CH), 128.6 (Ar-CH), 128.5



(Ar-CH), 127.7 (Ar-CH), 119.0 (Ar-C), 35.7 (CH₂), 31.0 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.2 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₅H₂₁O₁N₂Br₁S (M): *m/z* 356.0558 found 356.056.

2.1.4. *N*-(2',5'-Dimethylphenylcarbamothioyl) octanamide (3d). White, yield 83%, mp 89–91 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3448 (-NH), 3177, 2922, 1698 (C=O), 146 (100), 121 (26), 57 (50). EI-MS *m/z* (%), 306 (24.1), 291 (12.8), 306 (75), 179 (27.5), 165 (13.6), 164 (8.1), 127 (12.8). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.12 (1H, s, NH), 11.40 (1H, s, NH), 7.36 (1H, s, H-6'), 7.15 (1H, d, $J_{3',4'} = 8.0$ Hz, H-3'), 7.01 (1H, d, $J_{4',3'} = 8.0$ Hz, H-4'), 2.49 (obscured by DMSO signal, H-2), 2.25 (3H, s, CH₃), 2.13 (3H, s, CH₃), 1.55 (2H, q, $J_3 = 8.0$ Hz, H-3), 1.26 (8H, m), 0.86 (3H, t, $J_8 = 8.0$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 179.6 (C=S), 175.5 (C=O), 136.4 (Ar-C), 135.2 (Ar-C), 130.2 (Ar-CH), 130.0 (Ar-C), 127.6 (Ar-CH), 126.7 (Ar-CH), 35.68 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 22.0 (CH₂), 20.5 (CH₃), 17.1 (CH₃), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₇H₂₆O₁N₂S₁ (M): *m/z* 306.1766 found 306.1777.

2.1.5. *N*-((4'-Methoxyphenyl) carbamothioyl) octanamide (3e). White, yield 87%, mp 105 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3448 (-NH), 3192, 3030, 2931, 2858, 1694 (C=O), 1606, 1511, 1463, 1343, 1251, 1158, 1027, 833, 742, 613, 437. EI-MS *m/z* (%), 308 (32.9), 181 (7.8), 167 (4.7), 128 (1.1), 122 (14.6), 108 (19.9). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.34 (1H, s, NH), 11.34 (1H, s, NH), 7.49 (2H, d, $J_{2',3'/6',5'} = 8.0$ Hz, H-6', H-2'), 6.94 (2H, d, $J_{3',2'/5',6'} = 8.8$ Hz, H-3', H-5'), 2.45 (2H, t, $J_2 = 14.0$ Hz, H-2), 1.56 (2H, q, $J_3 = 12.0$ Hz, H-3), 1.26 (8H, m), 0.87 (3H, t, $J_8 = 6.0$ Hz, H-8); ¹³C-NMR (100 MHz, DMSO-*d*₆): δ_{C} 179.4 (C=S), 175.9 (C=O), 157.8 (Ar-C), 131.1 (Ar-C), 126.3 (Ar-CH × 2), 114.2 (Ar-CH × 2), 55.7 (-OCH₃), 36.2 (CH₂), 31.5 (CH₂), 28.9 (CH₂), 28.8 (CH₂), 24.8 (CH₂), 22.5 (CH₂), 20.7 (CH₂), 14.4 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₆H₂₄O₂N₂S (M): *m/z* 308.1588 found 308.155.

2.1.6. *N*-(3',4'-Dimethylphenylcarbamothioyl) octanamide (3f). White, yield 83%, mp 95.6 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3446 (-NH), 3176, 2921, 2853, 1698 (C=O), 1546, 1185, 1373, 1039, 808, 701, 556, 531 *m/z* (%), 306 (75), 291 (78), 207 (10.3), 179 (27.5), 165 (35.5), 164 (19.4) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.12 (1H, s, NH), 11.40 (1H, s, NH), 7.36 (1H, s, H-2'), 7.15 (1H, d, $J_{6',5'} = 8.0$ Hz, H-6'), 7.01 (1H, d, $J_{5',6'} = 8.0$ Hz, H-5'), 2.46 (2H, t, $J_2 = 12.0$ Hz, H-2), 2.25 (3H, s, CH₃), 2.13 (3H, s, CH₃), 1.57 (2H, q, $J_3 = 12.0$ Hz, H-3), 1.26 (8H, m), 0.87 (3H, t, $J_8 = 12.0$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 179.7 (C=S), 175.5 (C=O), 136.5 (Ar-C), 135.2 (Ar-C), 130.2 (Ar-CH), 130.0 (Ar-C), 127.6 (Ar-CH), 126.8 (Ar-CH), 35.7 (CH₂), 31.0 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 22.0 (CH₂), 20.5 (CH₂), 17.1 (CH₃ × 2), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₇H₂₆ON₂S (M): *m/z* 306.1766 found 306.1769.

2.1.7. *N*-(2',6'-Dimethylphenylcarbamothioyl) octanamide (3g). Yellowish orange crystals, yield 93%, mp 110 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3445 (-NH), 3177, 3030, 2921, 2853, 1699 (C=O), 1541, 1219, 1166, 1093, 765, 697, 607, 512, 458. *m/z* (%), 306 (54), 291 (100), 179 (10.2), 165 (60.7), 120 (19.4), 105 (11.1) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 11.72 (1H, s, NH), 11.39 (1H, s, NH), 7.14–7.07 (3H, m, Ar-H), 2.49 (obscured by DMSO signal, H-2), 2.13 (6H, s, C), 1.58 (2H, q, J_3 4.0 Hz, H-3),

1.28 (8H, m), 0.87 (3H, t, $J_8 = 6.0$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 180.1 (C=S), 175.2 (C=O), 136.0 (Ar-C), 134.9 (Ar-C × 2), 127.8 (Ar-CH), 127.3 (Ar-CH), 35.6 (CH₂), 31.0 (CH₂), 28.3 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 21.9 (CH₂), 17.7 (CH₃), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₇H₂₆ON₂S (M): *m/z* 306.1766 found 306.1770.

2.1.8. *N*-(2'-Methoxy-5'-nitrophenylcarbamothioyl) octanamide (3h). Yellowish orange crystals, yield 61%, mp 121 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3334 (-NH), 2945, 2918, 1695 (C=O), 1558, 1488, 1336, 1265, 1152, 1017, 839, 727, 634, 561, 456. *m/z* (%), 353 (52), 226 (8.3), 212 (5.1), 196 (100), 181 (4.4), 127 (41.3) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 13.09 (1H, s, NH), 11.59 (1H, s, NH), 9.74 (1H, d, $J_{6',4'} = 4.0$ Hz, H-6'), 8.15 (1H, dd, $J_{4',3'} = 4.0$ Hz, $J_{4',6'} = 8.0$ Hz, H-4'), 7.34 (1H, d, $J_{3'} = 8.0$ Hz, H-3'), 4.01 (3H, s, OCH₃), 2.49 (obscured by DMSO signal, H-2), 1.57 (2H, q, $J_3 = 12.0$ Hz, H-3), 1.26 (8H, m), 0.87 (3H, t, $J_8 = 8.0$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 178.1 (C=S), 175.6 (C=O), 155.3 (Ar-C), 139.7 (Ar-C), 127.3 (Ar-C), 122.2 (Ar-CH), 117.0 (Ar-CH), 111.3 (Ar-CH), 57.2 (-OCH₃), 35.6 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.2 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₆H₂₃O₄N₃S (M): *m/z* 353.1409 found 353.1413.

2.1.9. *N*-(2',6'-Dichlorophenylcarbamothioyl) octanamide (3i). White crystalline solid, yield 67%, mp 145 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3674 (-NH), 3162, 3040, 2924, 1690 (C=O), 1515, 1173, 784, 655, 615. FABP *m/z* (%), (M + I) 347.0 ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 11.86 (1H, s, NH), 11.62 (1H, s, NH), 7.54 (2H, d, $J_{3',5'} = 8.0$ Hz, H-3', H-5'), 7.38 (1H, t, $J_{4'} = 8.2$ Hz, H-4'), 2.49 (obscured by DMSO signal, H-2), 1.58 (2H, q, H-3), 1.58 (2H, q, $J_3 = 8.0$ Hz, H-3), 1.27 (8H, m), 0.87 (3H, t, $J_8 = 6.8$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 180.8 (C=S), 175.2 (C=O), 134.1 (Ar-C × 2), 133.7 (Ar-C), 129.7 (Ar-CH × 2), 128.4 (Ar-CH), 35.6 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.2 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₅H₂₁ON₂Cl₂S (M) *m/z* 347.0752 found 347.0746.

2.1.10. *N*-(2'-(Phenylthio)phenylcarbamothioyl) octanamide (3j). White, yield 51%, mp 143 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3446 (-NH), 3149, 2925, 1695 (C=O), 1525, 1472, 1234, 1164, 751, 782 545. *m/z* (%), 387.2 (M⁺ - I, 4.3), 277 (84.9), 200.0 (11.6), 186 (5.5), 109 (2.6) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.50 (1H, s, NH), 11.39 (1H, s, NH), 7.95 (1H, d, Ar-H), 7.42–7.19 (8H, m, Ar-H) 2.40 (2H, t, $J_2 = 7.6$ Hz, H-2), 1.52 (2H, q, $J_3 = 6.6$ Hz, H-3), 1.24 (8H, m), 0.86 (3H, t, $J_8 = 6.8$ Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_{C} 179.8 (C=S), 175.3 (C=O), 138.5 (Ar-C), 134.3 (Ar-C × 2), 133.2 (Ar-CH), 129.7 (Ar-CH × 2), 129.4 (Ar-CH × 2), 128.3 (Ar-CH), 127.5 (Ar-CH), 127.4 (Ar-CH), 127.1 (Ar-CH), 35.6 (CH₂), 31.0 (CH₂), 28.9 (CH₂ × 2), 24.3 (CH₂), 22.0 (CH₂), 13.89 (CH₃); HREI-MS (M⁺ - I): calculated for C₂₁H₂₆O₁N₂S₂ (M): *m/z* 386.1487 found 386.1478.

2.1.11. *N*-(2',3'-Dimethylphenylcarbamothioyl) octanamide (3k). Light brown, yield 71%, mp 82–84 °C; IR (ν_{\max} , cm⁻¹): (KBr disk) 3445 (-NH), 3175, 3034, 2922, 2853, 1698 (C=O), 1546, 1467, 1374, 1262, 1176, 1094, 1072, 1020, 786, 724, 704, 608, 541. EI-MS *m/z* (%), 306 (47.5), 105 (14.9), 121 (100.0), 128 (2.1), 165 (65.5), 179 (15.2), 207 (13.2), 291 (66.6) ¹H-NMR (400 MHz, DMSO-*d*₆): δ_{H} (ppm) 12.07 (1H, s, NH), 11.404 (1H, s, NH), 7.25 (1H, m, Ar-H), 7.10 (2H, m, Ar-H), 2.49 (obscured by DMSO



signal, H-2), 2.57 (3H, s, CH₃), 2.06 (3H, s, CH₃), 1.57 (2H, q, J₃ = 4.0 Hz, H-3), 1.26 (8H, m), 0.87 (3H, t, J₈ = 8.0 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_C 180.1 (C=S), 175.5 (C=O), 137.1 (Ar-C), 136.5 (Ar-C), 132.2 (Ar-C), 128.4, 125.3, 124.7 (Ar-CH), 35.7 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 22.0 (CH₂), 19.9 (CH₃), 13.9 (CH₃); 13.8 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₇H₂₆ON₂S (M): *m/z* 306.1766 found 306.1755.

2.1.12. *N*-((2'-Iodophenyl) carbamothioyl) octanamide (3l). Dark purple color, yield 63%, mp 96–98 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3451 (–NH), 3179, 1702 (C=O), 1535, 1515, 1149, 1021, 7537, 717. FABP *m/z* (%) (M + I) 405.1 ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm): 12.2 (1H, s, NH), 11.5 (1H, s, NH), 7.90 (1H, app dd, J_{6',5'} = 8.0 Hz, J_{6',4'} = 0.8 Hz, H-6'), 7.63 (1H, d, J_{3',4'} = 8.0 Hz, H-3'), 7.44 (1H, app td, J_{5'(6',4')} = 8.0 Hz, J_{5',3'} = 0.4 Hz, H-5'), 7.05 (1H, app td, J_{4'(3',5')} = 7.6 Hz, J_{4',6'} = 0.8 Hz, H-4'), 2.49 (obscured by DMSO signal, H-2), 1.56 (2H, q, J₃ = 7.2 Hz, H-3), 1.28 (8H, m), 0.87 (3H, t, J = 6.6 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_C 180.2 (C=S), 175.5 (C=O), 140.0 (Ar-C), 138.8 (Ar-CH), 128.8 (Ar-CH), 128.6 (Ar-CH), 128.4 (Ar-CH), 97.1 (Ar-C), 35.7 (CH₂), 31.0 (CH₂), 28.3 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₅H₂₁OI₁N₂S₁ (M): *m/z* 404.0419 found 404.0410.

2.1.13. *N*-(4'-(Trifluoromethyl) phenylcarbamothioyl) octanamide (3m). White needle-like crystals, yield 74%, mp 84–86 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3345 (–NH), 3178, 2962, 2930, 1689 (C=O), 1542, 1325, 1170, 1130, 1067, 1020, 916, 722, 670, 617, 540. EI-MS *m/z* (%), 346 (81.9), 277 (2.0), 219 (30.8), 205 (3.7), 186 (5.8), 161 (100), 145 (19.0), 142 (6.2), 128 (2.0). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm) 12.683 (1H, s, NH), 11.54 (1H, s, NH), 7.90 (2H, d, J_{3',2'/5',6'} = 8.8 Hz, H-3', H-5'), 8.03 (2H, d, J_{2',3'/6',5'} = 8.8 Hz, H-2', H-6'), 2.09 (2H, t, J₂ = 15.2 Hz, H-2), 1.57 (2H, app q, J₃ = 14.4 Hz, H-3), 1.28–1.22 (8H, m), 0.86 (3H, t, J₁₂ = 13.6 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_C 179.1 (C=S), 175.6 (C=O), 141.5 (C), 126.3 (C), 125.89/125.87 (C), 125.7 (Ar-CH), 125.7 (Ar-CH), 125.7 (Ar-CH), 124.4 (Ar-CH), 35.8 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.2 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₆H₂₁O₁N₂F₃S₁(M): *m/z* 346.1327 found 346.1333.

2.1.14. *N*-((2'-Hydroxyphenyl) carbamothioyl) octanamide (3n). White, yield 52%, mp 149.8 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3436 (–NH), 3182, 2922, 1664 (C=O), 1548, 1458, 1183, 1038, 746, 617, 456. EI-MS *m/z* (%), 294 (4.0), 167 (3.0), 152 (4.5), 127 (5.1), 108 (3.0), 91 (5.4). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm) 12.73 (1H, s, NH), 11.27 (1H, s, NH), 10.13 (1H, s, OH), 8.51 (1H, app dd, J_{6',5'} = 8.0 Hz, J_{6',4'} = 1.2 Hz, H-6'), 7.05 (1H, app td, J_{4'(5',3')} = 8.0 Hz, J_{4',6'} = 1.2 Hz, H-4'), 6.91 (1H, app dd, J_{3',4'} = 8.0 Hz, J_{3',5'} = 1.2 Hz, H-3'), 76.81 (1H, td, J_{5'(6',4')} = 8.0 Hz, J_{5',3'} = 1.2 Hz, H-5'), 1.56 (2H, q, J₃ = 13.6 Hz, H-3), 1.26 (8H, m, H-3, H-4, H-5, H-6, H-7), 0.87 (3H, t, J₈ = 6.8 Hz, H-8); ¹³C-NMR (125 MHz, DMSO-*d*₆): δ_C 177.2 (C=S), 175.1 (C=O), 148.7 (Ar-C), 126.2 (Ar-CH), 125.9 (Ar-C), 122.9 (Ar-CH), 118.2 (Ar-CH), 114.9 (Ar-CH), 35.7 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 24.3 (CH₂), 22.0 (CH₂), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₅H₂₂O₂N₂S (M): *m/z* 294.1402 found 294.1399.

2.1.15. *N*-((4'-Ethylphenyl) carbamothioyl) octanamide (3o). White, yield 86%, mp 74.4 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3345 (–NH), 3189, 2924, 2852, 1692 (C=O), 1545, 1163, 1060,

1023, 903, 835, 725, 536, 505, 433. EI-MS *m/z* (%), 306 (68.2), 179 (21.5), 165 (7.4), 128 (3.1), 121 (23.9), 106 (45.6). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm) 12.45 (1H, s, NH), 11.36 (1H, s, NH), 7.51 (2H, d, J_{2',3'/6',5'} = 8.0 Hz, H-6', H-2'), 7.22 (2H, d, J_{3',2'/5',6'} = 8.0 Hz, H-3', H-5'), 2.62 (2H, q, J_{1''} = 7.6 Hz, H-1''), 2.45 (2H, t, J₂ = 14.4 Hz, H-2), 1.55 (2H, q, J₃ = 10.8 Hz, H-3), 1.25 (8H, m, H-3, H-4, H-5, H-6, H-7), 1.19 (3H, t, J_{2''} = 15.2 Hz, H-2''), 0.87 (3H, t, J₈ = 13.2 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_C 178.7 (C=O), 175.5 (C=S), 175.6 (C=O), 141.8 (Ar-C), 135.4 (Ar-C), 127.8 (Ar-CH × 2), 124.1 (Ar-CH × 2), 35.7 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 27.7 (CH₂), 24.9 (CH₂), 22.0 (CH₃), 15.5 (CH₃), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₅H₂₂O₂N₂S (M): *m/z* 306.1766 found 306.1777.

2.1.16. *N*-(3',4'-Dichlorophenylcarbamothioyl) dodecanamide (3p). White needle-like crystals, yield 74%, mp 84–86 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3445 (–NH), 3183, 2921, 2850, 1700 (C=O), 1586, 1538, 1472, 1404, 1163, 1032, 809, 731, 616. EI-MS *m/z* (%), 402 (3.9), 332 (2.9), 204 (26.9), 183 (91.5). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm) 12.49 (1H, s, NH), 11.53 (1H, s, NH), 8.06 (1H, d, J_{2',6'} = 2.0 Hz, H-2'), 7.64 (1H, d, J_{5',6'} = 8.8 Hz, H-5'), 7.57 (1H, app dd, J_{6',5'} = 8.4 Hz, J_{6',2'} = 2.4 Hz), 2.45 (2H, t, J₂ = 14.4 Hz, H-2), 1.56 (2H, q, J₃ = 13.2 Hz, H-3), 1.23 (8H, m), 0.87 (3H, t, J₈ = 6.8 Hz, H-8); ¹³C-NMR (75 MHz, DMSO-*d*₆): δ_C 179.7 (C=S), 175.8 (C=O), 138.4 (Ar-C), 131.1 (Ar-C), 130.7 (Ar-CH), 128.5 (Ar-C), 126.4 (Ar-CH), 125.2 (Ar-CH), 36.1 (CH₂), 31.7 (CH₂), 30.9 (CH₂), 29.4 (CH₂), 29.4 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 28.8 (CH₂), 24.6 (CH₂), 24.5 (CH₂), 14.3 (CH₃); HREI-MS (M⁺ - I): calculated for C₁₉H₂₈ON₂Cl₂S (M): *m/z* 402.1299 found 402.1295.

2.1.17. *N*-((4-Acetylphenyl)carbamothioyl) octanamide (3q). White, yield 77%, mp 127.4 °C; IR (ν_{max}, cm⁻¹): (KBr disk) 3424 (–NH), 2913, 1659 (C=O), 1596, 1531, 1277, 1176, 1030, 837, 592, 484, 433. EI-MS *m/z* (%), 320 (11.1), 193 (5.2), 134 (10.9), 128 (16.4), 120 (13.2). ¹H-NMR (400 MHz, DMSO-*d*₆): δ_H (ppm) 12.75 (1H, s, NH), 11.52 (1H, s, NH), 7.98 (2H, d, J_{3',2'/5',6'} = 8.4 Hz, H-3', H-5'), 7.87 (2H, d, J_{2',3'/6',5'} = 8.8 Hz, H-6', H-2'), 2.56 (3H, s, –OCH₃), 2.47 (2H, t, J₂ = 16.0 Hz, H-2), 1.57 (2H, q, J₃ = 13.6 Hz, H-3), 1.25 (8H, m, H-3, H-4, H-5, H-6, H-7), 0.87 (3H, t, J₈ = 6.6 Hz, H-8); ¹³C-NMR (125 MHz, DMSO-*d*₆): δ_C 196.8 (C=O), 178.7 (C=S), 175.6 (C=O), 141.9 (Ar-C), 134.1 (Ar-C), 128.9 (Ar-CH × 2), 123.3 (Ar-CH × 2), 35.7 (CH₂), 31.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 26.6 (CH₂), 24.2 (CH₂), 22.0 (CH₃), 13.9 (CH₃); HREI-MS (M⁺ - I): calculated for C₂₀H₂₄O₂N₂S₁ (M): *m/z* 320.1558 found 320.1588.

2.2. Urease inhibition assay

Antiurease activity was assessed by employing the indophenol method. Here, the synthesized compounds (inhibitors) were dissolved in dimethyl sulfoxide and serial dilution was made in the range of 1000–0.976 μM concentration, with thiourea used as the reference inhibitor of urease. The assays were performed in a 96-well plate, with incubation with phosphate buffer (10 μL, 50 mmol, K₂HPO₄), jack bean urease (20 μL, 5 units per mL) from Uni-Chem-UK, catalog no. U30550-2E, and inhibitor (20 μL) for 10 min at 37 °C. Then, urea was added as a substrate (40 μL, 20 mM) and the mixture was incubated again for 50 min at 37 °C. After incubation, the reaction mixture was placed at room temperature, and then phenol reagent (40 μL) was added, which



was a mixture of phenol (1.0% w/v, in water) and sodium nitroprusside (0.005% w/v, in water) and alkali reagent (75 μ L) comprising sodium hydroxide (0.5%, in water) and sodium hypochlorite (0.1% active chlorine, in water). Then, the well plate was placed at room temperature and a micro plate reader (LT-4500, Labtech International Ltd, UK) was employed to note the absorption of each well at 625 nm and the percentage urease inhibition was determined using the following formula. The blank was run in the same manner with water used instead of the inhibitor.^{21–24}

$$\% \text{ Urease inhibition} = \{1 - T/C\} \times 100$$

where T is the absorbance of the inhibitory well and C is the absorbance of the initial wells without the inhibitor. The assays were performed in triplicate and the results were presented as the mean \pm SEM, whereas IC_{50} , Lineweaver–Burk plots, the inhibition constant (K_i), $V_{\max(\text{app})}$, $K_{m(\text{app})}$ for the kinetics studies and the binding mechanism were determined using GraphPad PRISM 7.0.

2.3. Molecular docking and dynamics studies

2.3.1. Protein structure and preparation of the newly synthesized compounds. For binding mode prediction of the competitive inhibitors using docking studies in urease enzyme, its X-ray structure (PDB ID 4H9M) was downloaded from Protein Data Bank (PDB) (<https://www.rcsb.org/>). Its structure was refined by using the protein preparation wizard embedded in Schrodinger software (www.schrodinger.com). All the co-crystal reagents were removed, and missing atoms along with hydrogen atoms were added. The ionization states of the polar residues were generated at pH 7. Finally, the complete protein structure was minimized by applying the OPLS 2005 force field to remove steric clashes among the side chains by allowing an RMS deviation of 0.3 Å from its original conformation. Small synthesized organic compounds were drawn in maestro and then prepared using the LigPrep tool. Stereoisomers and

possible ionization states were generated by keeping 32 low energy conformers of each compound.


2.3.2. Grid generation and docking protocol. Using the prepared urease enzyme, a grid box was generated around the active site containing two nickel ions. From the central coordinates 17.5, 36.56, 20.48 of the active site, the cubic box was taken as 10 Å in each dimension by setting the parameters, which included a cutoff radius scaling of 0.25 and van der Waals factor of 1.0. Then the **3c** and **3g** compounds were docked using the standard precision mode (SP) of GLIDE software. All the other default parameters were used, and the final docked pose of each compound was selected based on the highest Glide score.²⁵

2.3.3. Molecular dynamics (MD) simulation studies. The MD simulations of both complexes (**3c**-urease and **3g**-urease) were performed at 100 ns²⁶ using the NAMD tool. The input files were prepared using AMBER21 tools.²⁷ The ligand topology files were prepared by antechamber, while the LeaP program was used to add missing hydrogen to the protein.²⁸ The solvation of protein–ligand complexes was done in a periodic box of 10 Å using the TIP3P water model.²⁹ The system was neutralized by adding Na^+ and Cl^- counter ions prior to the minimization step. Two forcefields, *i.e.*, ff14SB and GAFF, were used for the protein and ligand, respectively.³⁰ To avoid the energy clashes, the systems were relaxed by minimization at 10 000 steps. After removing the clashes of systems, the solvation system was equilibrated at 300 K. Three additional equilibrations were run by increasing the temperature from 200 K to 250 K and 300 K to maintain the stability of the systems. Then the systems were subjected to 100 ns simulation in the production run. The MD trajectories were stored at every 2 ps during the production run. The analysis was carried out by the VMD and R package.

3. Results and discussion

3.1. Chemistry

A series of thiourea-based molecules was prepared by a simple and efficient synthetic protocol by following the scheme



Scheme 1 Synthesis of the alkyl chain-linked thiourea derivatives (3a–3q).



explained in the experimental section with good to excellent yields. The different acyl derivatives were treated with potassium thiocyanate in dried acetone at 60–70 °C, which afforded the acyl isothiocyanate. The intermediate obtained then was subsequently treated with various substituted aniline derivatives in the presence of dried acetone and refluxed again at 60–70 °C. The reaction mixture was monitored through thin-layered chromatographic analysis. The newly synthesized derivatives of thiourea **3a–3p** (Scheme 1) were characterized by various spectroscopic techniques, including $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, IR, and EIMS, and the details are shown in Section 2.1.

3.2. Urease inhibition


The successfully synthesized compounds were evaluated for their *in vitro* anti-urease activity. The enzyme (urease) inhibition data (Table 1) showed that all the compounds were active against urease. Thiourea was used as a reference in the urease inhibition assay with an IC_{50} value of 18.61 μM . The thiourea derivatives with 4'-bromo (**3c**) and 2,6-dimethyl (**3g**) substituents on the phenyl ring showed excellent activities against urease with IC_{50} values of 10.65 and 15.19 μM , respectively, compared to standard thiourea (IC_{50} = 18.61 μM). The other dimethyl substituents bearing thiourea derivatives (**3f**), (**3k**), and (**3d**) showed moderate to weak activity with IC_{50} values of 40.22, 46.17, and 60.11 μM , respectively.


The urease inhibition activity of other halogen-bearing thiourea derivatives (**3i**), (**3p**) with a dichloro substituent on the phenyl showed good activity with slightly higher IC_{50} values of 22.03 and 20.16 μM , compared to the reference thiourea (IC_{50} = 18.61 μM). While, in the case of the 2'-iodo substituent, the inhibitory activity was reduced with an IC_{50} value of 31.07 μM .

Moving toward other thiourea-based derivatives, the 4'-methoxyphenyl substituent-bearing derivative (**3e**) showed weak activity with an IC_{50} value of 35.17 μM , while the induction of the electron-withdrawing nitro group on the phenyl ring improved the inhibitory activity of the thiourea derivative with IC_{50} values of 31.09 μM (**3a**) and 30.65 μM (**3h**). Further, the derivatives (**3m**) and (**3b**) bearing the 4'-trifluoromethyl substituent also showed moderate to weak activity with IC_{50} values of 31.16 and 35.17 μM .

The other derivatives bearing 2'-thiophenyl (**3j**), 2'-hydroxy (**3n**), 4'-ethyl (**3o**), and 4'-acetyl (**3q**) also demonstrated inhibitory activities with IC_{50} values of 39.11, 35.58, 42.78, and 53.74 μM . The most potent compounds (**3c**) and (**3g**) could potentially serve as leads for the development of new urease inhibitors.


Kinetic studies were performed for the two most potent compounds **3c** (IC_{50} = 10.65 \pm 0.45 μM) and **3g** (IC_{50} = 15.19 \pm 0.58 μM) at five different concentrations, namely 0.0, 5.0, 10.0, 15.0, and 20.0 μM , along with four different conditions of urea (0.5, 1.0, 2.0, 4.0) as the substrate. The inhibition constant (K_i) as well as the inhibition mode of both inhibitors (**3c** and **3g**)



Table 1 IC_{50} and kinetics parameters of the synthesized thiourea derivatives

Compound	Phenyl substituents	IC_{50} (μM); mean \pm SEM (% inhibition)	$V_{max(app)}^a$ ($\mu M \text{ min}^{-1}$)	$K_m(app)^b$ (mM)	K_i^c (μM)	Mode of inhibition
3a	2'-NO ₂ , 4'-OCH ₃	31.09 \pm 0.42 (95.2)	—	—	—	—
3b	4'-CF ₃	35.17 \pm 0.46 (87.2)	—	—	—	—
3c	4'-Br	10.65 \pm 0.45 (96.3)	6.91	4.17	1.52	Competitive
3d	2',5'-diCH ₃	60.11 \pm 0.78 (61.3)	—	—	—	—
3e	4'-OCH ₃	35.17 \pm 0.56 (71.2)	—	—	—	—
3f	3',4'-diCH ₃	40.22 \pm 0.45 (76.2)	—	—	—	—
3g	2',6'-diCH ₃	15.19 \pm 0.58 (96.3)	15.63	6.09	9.28	Competitive
3h	2'-OCH ₃ , 5'-NO ₂	30.65 \pm 0.75 (88.1)	—	—	—	—
3i	2',3'-diCl	22.03 \pm 0.45 (91.4)	—	—	—	—
3j	2'-thiophenyl	39.11 \pm 0.72 (86.5)	—	—	—	—
3k	2',3'-diCH ₃	46.17 \pm 0.78 (85.8)	—	—	—	—
3l	2'-I	31.07 \pm 0.58 (88.7)	—	—	—	—
3m	4'-CF ₃	31.16 \pm 0.25 (95.9)	—	—	—	—
3n	2'-OH	35.58 \pm 0.45 (87.4)	—	—	—	—
3o	4'-CH ₂ CH ₃	42.78 \pm 0.54 (87.4)	—	—	—	—
3p	3',4'-diCl	20.16 \pm 0.48 (85.2)	—	—	—	—
3q	4'-Acetyl	53.74 \pm 0.58 (86.2)	—	—	—	—
Thiourea ^d	—	18.61 \pm 0.11 (92.1)	18.61	2.18	18.18	Competitive

^a $V_{max(app)}$ = maximum velocity that measures the rate of reaction of urease enzyme at 20 μM concentration of the inhibitor. ^b $K_m(app)$ = Michaelis-Menten constant that measures the affinity of urease for the substrate at 20 μM concentration of the inhibitor. ^c K_i (μM) = Inhibition constant derived from Lineweaver-Burk and Dixon plots. ^d Reference inhibitor of urease.






Fig. 2 Mode of inhibition exhibited by **3c** and **3g** as explained by (a) primary, (b) secondary Lineweaver–Burk and (c) Dixon plots.

were determined by doing the enzymatic kinetics studies as mentioned above to evaluate whether the inhibitors were competitive, non-competitive, or mixed type.

Lineweaver–Burk plots were drawn to assess the mode of inhibition by evaluating the effect of the inhibitors (**3c** and **3g**) on V_{\max} and K_m . The effects of the inhibitors (compounds) on

V_{\max} and K_m were determined to assess the mode of inhibition by Lineweaver–Burk plots. The K_m of urease enzyme increased while the V_{\max} was at 20 μM for the inhibitor (**3c** and **3g**), which showed that both the inhibitors inhibited the enzyme in competitive ways. The K_i values for each inhibitor were determined by Lineweaver–Burk secondary plots (slope of each line




Fig. 3 Predicted binding modes of **3c** (A and B) and **3g** (C and D) inhibitors, (A) Sticks model of the binding at the site surface of the urease enzyme, (B) Binding mode in the urease enzyme (cartoon structure) showing the hydrogen bonding (yellow dotted lines), (C) Sticks model of the binding site surface of the urease enzyme, (D) Sticks model of the binding site surface of the urease enzyme showing the hydrogen bonding interaction. Brown spheres represent nickel ions.



vs. different concentrations of **3c** and **3g**) and were further confirmed by Dixon plot. It was concluded from the kinetic studies that both the compounds (**3c** and **3g**) were competitive inhibitors with K_i values of 1.52 and 9.28 μM , respectively (Table 1). The enzymatic kinetics of the most active compounds are presented below in Fig. 2.

3.3. Molecular docking and simulation studies

The binding modes of the competitive inhibitors were predicted using molecular docking simulation studies. Both **3c** and **3g** compounds docked well in the binding site of the urease enzyme (as shown in Fig. 3a and c). It was also observed that both compounds made hydrogen bonding interactions with Arg439 and Ala440 residues of the backbone atoms of the urease enzyme (Fig. 3b and d). The long aliphatic tail of both compounds residing in the channel was present toward the solvent exposed site. To further validate the predicted binding mode of the compounds, MD simulations were performed for 100 ns time. The simulation trajectories were analyzed to measure both complexes structural stability by calculating the

root mean square deviation (RMSD), root mean square fluctuations (RMSF), and radius of gyration (rGyr) over the whole simulation time.

The RMSD of the main chain was calculated from the trajectories of the urease-**3c** and **3g** complexes. It was observed that both complexes remained at a ~ 2 – 2.5 Å backbone RMS deviation until 30 ns, as shown in Fig. 4A and B. Between the ranges of 30 ns to 60 ns, urease bound with the **3c** compound, and attained an utmost RMSD value of ~ 3.25 Å, while urease bound with **3g** compound attained a maximum deviation of ~ 3 Å. Irregular deviations in the RMSD of both complexes were observed during 30 to 60 ns and then the systems gained stability in the range of ~ 2 to 2.5 Å. The average RMSD value of the urease-**3g** complex was 2.35 ± 0.29 Å, while urease-**3c** showed an average RMSD value of 2.37 ± 0.31 Å. The RMSD of the **3c** and **3g** compounds was also plotted,³¹ where both ligands remained in the range of ~ 2 Å except for **3g**, which showed a deviation of more than 2 Å from 80 to 100 ns. The RMSD graphs suggested that urease retained a stable conformation when bound to both **3c** and **3g** compounds throughout the simulation time.




Fig. 4 Molecular dynamics simulation analysis. (A and B) Calculated RMSD values of urease enzyme in complex with **3c** and **3g** compounds, (C) Comparison between the RMSF values of both complexes, (D) Compactness comparison of urease bound to **3c** and **3g**.



Table 2 Calculated ADMET properties of the newly designed thiourea derivatives^a

ID	MW	HBD	HBA	QPlogPo/w	QPlogHERG	QPPCaco2	QPlogBB	QPlogKhsa	CNS
3a	353.435	1	4	4.489	-5.545	479.455	-1.358	0.715	-2
3b	402.517	1	2	7.508	-6.365	2481.758	-0.446	1.543	0
3c	357.308	1	2	5.536	-5.761	2483.855	-0.219	0.906	0
3d	306.465	1	2	5.638	-5.613	3056.075	-0.316	1.078	0
3e	308.438	1	3	5.057	-5.705	2485.241	-0.467	0.774	0
3f	306.465	1	2	5.553	-5.603	2486.829	-0.416	1.067	0
3g	306.465	1	2	5.603	-5.577	3520.209	-0.247	1.042	0
3h	353.435	1	4	4.403	-5.618	324.484	-1.584	0.734	-2
3i	347.302	1	2	5.904	-5.604	3210.64	0.007	0.979	1
3j	386.569	1	2	7.180	-7.006	3141.839	-0.377	1.497	0
3k	306.465	1	2	5.596	-5.635	2949.132	-0.327	1.055	0
3l	404.308	1	2	5.632	-5.792	2909.121	-0.142	0.923	0
3m	346.41	1	2	5.947	-5.756	2483.153	-0.132	1.03	0
3n	294.411	2	3	4.207	-5.712	935.46	-0.934	0.517	-1
3o	306.465	1	2	5.636	-5.802	2487.485	-0.484	1.047	0
3p	403.409	1	2	7.463	-6.241	3205.714	-0.295	1.491	0
3q	320.449	1	4	4.447	-5.784	791.161	-1.065	0.648	-2

^a MW = molecular weight, HBD = hydrogen bond donor, HBA = hydrogen bond acceptor, QPlogPo/w (-2.0 to 6.5) = predicted octanol/water partition coefficient, CNS (-2 to +2) = predicted central nervous system activity, QPlogHERG (<-5) = predicted IC₅₀ value for blockage of HERG K⁺ channels, QPCaco2 (<25 poor, > 500 great) = predicted Caco2 cell permeability in nm s⁻¹, QPlogBB (-3.0 to 1.2) = predicted brain/blood partition coefficient, QPlogKhsa (-1.5 to 1.5) = prediction of binding to human serum albumin.

To determine the dynamic behavior of the protein residues when bound to these compounds, RMSF values were calculated. The RMSF values of urease residues showed fluctuations from a range of ~0.5–4 Å in the entire simulation period when bound with the **3c** compound, while the RMSF of the urease-**3g** complex showed a maximum fluctuation of ~3 Å (Fig. 4C). RMSF analysis revealed that urease showed more flexibility when bound to the **3c** compound compared to the **3g** compound at some frames. During the MD simulations, the main chain RMSF was determined over the trajectories and averaged over each residue for both complexes, which showed that the flexibility of amino acids was highest in the region 590–610. The start and end residues also showed high RMSF values as these were present on C and N terminals.

The radius of gyration provides an insight into the overall protein compactness over time. Fig. 4D shows the rGyr plots of both complexes for 100 ns-long simulation at 310 K. It shows that when **3c** and **3g** were bound with urease, the maximum rGyr of the complex reached ~31.1 Å and ~31.2 Å during 50–60 ns, respectively. The overall trajectories trend showed that rGyr remained similar for both complexes, except for minor deviations at the end of the simulations.

We also calculated the physicochemical properties of the synthesized compounds, as shown in Table 2. Most of the compounds were in acceptable octanol/water partition coefficient range, except for **3b**, **3j**, and **3p**. Similarly, they showed good predicted cell permeability and an acceptable brain/blood partition coefficient. However, these compounds showed little higher predicted IC₅₀ values for HERG K⁺ channels blockage.

4. Conclusion

In conclusion, the urease inhibition activity of synthetic alkyl chain-conjugated thiourea derivatives demonstrated *N*-(2'-

bromophenyl)carbamothioyl)octanamide (**3c**) was the most active molecule among the series with an IC₅₀ value of 10.65 ± 0.45 μM compared to standard thiourea (IC₅₀ 18.61 ± 0.11 μM). Further compound *N*-(2',6'-dimethyl phenyl carbamothioyl) octanamide (**3g**) also exhibited good activity with an IC₅₀ value of 18.61 ± 0.11 μM. The enzymatic kinetics and molecule docking studies showed that these compounds competitively bind with the urease enzyme, which is crucial for designing urease-targeted inhibitors. The complexes remained compact, and no large deviation of the urease backbone and compounds original poses were observed throughout the simulations. As a result, our findings suggest that this new family of urease inhibitors could be employed to design and assess prospective treatments for infections caused by urease-producing bacteria.

Conflicts of interest

We wish to confirm that there are no known conflicts of interest associated with this publication.

Acknowledgements

We thank Higher Education Commission of Pakistan for providing grant 8094/Balochistan/NRPU//R&D/HEC/2017 to purchase computational resources.

References

- 1 A. Hameed, K. M. Khan, S. T. Zehra, R. Ahmed, Z. Shafiq, S. M. Bakht, M. Yaqub, M. Hussain, A. d. I. V. de León and N. Furtmann, *Bioorg. Chem.*, 2015, **61**, 51–57.
- 2 W.-K. Shi, R.-C. Deng, P.-F. Wang, Q.-Q. Yue, Q. Liu, K.-L. Ding, M.-H. Yang, H.-Y. Zhang, S.-H. Gong and M. Deng, *Bioorg. Med. Chem.*, 2016, **24**, 4519–4527.



- 3 H. Mobley, M. D. Island and R. P. Hausinger, *Microbiol. Mol. Biol. Rev.*, 1995, **59**, 451–480.
- 4 A. Saeed, S.-u. Rehman, P. A. Channar, F. A. Larik, Q. Abbas, M. Hassan, H. Raza, U. Flörke and S.-Y. Seo, *J. Taiwan Inst. Chem. Eng.*, 2017, **77**, 54–63.
- 5 F. A. Larik, M. Faisal, A. Saeed, P. A. Channar, J. Korabecny, F. Jabeen, I. A. Mahar, M. A. Kazi, Q. Abbas and G. Murtaza, *Bioorg. Chem.*, 2019, **86**, 473–481.
- 6 K. Stingl, K. Altendorf and E. P. Bakker, *Trends Microbiol.*, 2002, **10**, 70–74.
- 7 P. Krishnamurthy, M. Parlow, J. B. Zitzer, N. B. Vakil, H. L. Mobley, M. Levy, S. H. Phadnis and B. E. Dunn, *Infect. Immun.*, 1998, **66**, 5060–5066.
- 8 K. Kappaun, A. R. Piovesan, C. R. Carlini and R. Ligabue-Braun, *J. Adv. Res.*, 2018, **13**, 3–17.
- 9 A. Hamad, M. A. Khan, I. Ahmad, R. Khalil, M. Khalid, U. Abbas, R. Azhar, J. Uddin, G. E.-S. Batiha and A. Khan, *Sci. Rep.*, 2021, **11**, 1–14.
- 10 S. Benini, W. R. Rypniewski, K. S. Wilson, S. Miletta, S. Ciurli and S. Mangani, *Structure*, 1999, **7**, 205–216.
- 11 M. W. Pinkse, C. S. Maier, J. I. Kim, B. H. Oh and A. J. Heck, *J. Mass Spectrom.*, 2003, **38**, 315–320.
- 12 D. J. Evans Jr, D. G. Evans, S. S. Kirkpatrick and D. Y. Graham, *Microb. Pathog.*, 1991, **10**, 15–26.
- 13 P. Kosikowska and Ł. Berlicki, *Expert Opin. Ther. Pat.*, 2011, **21**, 945–957.
- 14 A. Rauf, S. Shahzad, M. Bajda, M. Yar, F. Ahmed, N. Hussain, M. N. Akhtar, A. Khan and J. Jończyk, *Bioorg. Med. Chem.*, 2015, **23**, 6049–6058.
- 15 Y. Gull, N. Rasool, M. Noreen, A. Altaf, S. Musharraf, M. Zubair, F.-U.-H. Nasim, A. Yaqoob, V. DeFeo and M. Zia-Ul-Haq, *Molecules*, 2016, **21**, 266.
- 16 L. V. Modolo, A. X. de Souza, L. P. Horta, D. P. Araujo and A. de Fatima, *J. Adv. Res.*, 2015, **6**, 35–44.
- 17 B. Ali, K. M. Khan, S. Hussain, S. Hussain, M. Ashraf, M. Riaz, A. Wadood and S. Perveen, *Bioorg. Chem.*, 2018, **79**, 34–45.
- 18 M. Taha, N. H. Ismail, S. Imran, A. Wadood, F. Rahim, K. M. Khan and M. Riaz, *Bioorg. Chem.*, 2016, **66**, 80–87.
- 19 A. Arshia, A. Khan, K. M. Khan, S. M. Saad, N. I. Siddiqui, S. Javaid, S. Perveen and M. I. Choudhary, *Med. Chem. Res.*, 2016, **25**, 2666–2679.
- 20 S. Yaqoob, S. Rahim, A. M. Bhayo, M. R. Shah, A. Hameed and M. I. Malik, *ChemistrySelect*, 2019, **4**, 10046–10053.
- 21 M. Ahmed, M. A. Qadir, A. Hameed, M. N. Arshad, A. M. Asiri and M. Muddassar, *Biochem. Biophys. Res. Commun.*, 2017, **490**, 434–440.
- 22 M. Imran, S. Waqar, K. Ogata, M. Ahmed, Z. Noreen, S. Javed, N. Bibi, H. Bokhari, A. Amjad and M. Muddassar, *RSC Adv.*, 2020, **10**, 16061–16070.
- 23 M. Ahmed, M. Imran, M. Muddassar, R. Hussain, M. U. Khan, S. Ahmad, M. Y. Mehboob and S. Ashfaq, *J. Mol. Struct.*, 2020, **1220**, 128740.
- 24 S. A. A. S. Tirmazi, M. A. Qadir, M. Ahmed, M. Imran, R. Hussain, M. Sharif, M. Yousaf and M. Muddassar, *J. Mol. Struct.*, 2021, **1235**, 130226.
- 25 T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, *J. Med. Chem.*, 2004, **47**, 1750–1759.
- 26 D. Elebeedy, I. Badawy, A. A. Elmaaty, M. M. Saleh, A. Kandeil, A. Ghanem, O. Kutkat, R. Alnajjar, A. I. Abd El Maksoud and A. A. Al-Karmalawy, *Comput. Biol. Med.*, 2022, 105149.
- 27 D. A. Case, H. M. Aktulga, K. Belfon, I. Ben-Shalom, S. R. Brozell, D. Cerutti, T. Cheatham, V. W. D. Cruzeiro, T. Darden and R. E. Duke, 2021.
- 28 J. Zou, C. Tian and C. J. Simmerling, *J. Comput.-Aided Mol. Des.*, 2019, **33**, 1021–1029.
- 29 W. L. Jorgensen, J. Chandrasekhar and J. D. Madura, *J. Chem. Phys.*, 1983, **79**, 926.
- 30 Y. Duan, C. Wu, S. Chowdhury, M. C. Lee, G. Xiong, W. Zhang, R. Yang, P. Cieplak, R. Luo and T. Lee, *J. Comput. Chem.*, 2003, **24**, 1999–2012.
- 31 A. Mahmoud, A. Mostafa, A. A. Al-Karmalawy, A. Zidan, H. S. Abulhair, S. H. Mahmoud, M. Shehata, M. M. Elhefnawi and M. A. J. H. Ali, *Heliyon*, 2021, **7**, e07962.

